Skip to main content

Pipamperone









Pipamperone


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search


Not to be confused with Pirenperone.









































































Pipamperone
Pipamperone.svg
Clinical data
Synonyms McN-JR 3345; R-3345

AHFS/Drugs.com
 International Drug Names
Routes of
administration		 Oral
ATC code

  • N05AD05 (WHO)
Identifiers
CAS Number

  • 1893-33-0 ☒N

PubChem CID
  • 4830
IUPHAR/BPS
  • 92
ChemSpider

  • 4664 ☑Y
UNII
  • 5402501F0W
KEGG

  • D02622 ☑Y
ChEMBL

  • ChEMBL440294 ☑Y
ECHA InfoCard
100.119.828 Edit this at Wikidata
Chemical and physical data
Formula
C21H30FN3O2
Molar mass 375.480 g/mol
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
 ☒N☑Y (what is this?)
  (verify)

Pipamperone (INN, USAN, BAN), also known as carpiperone and floropipamide or fluoropipamide, and as floropipamide hydrochloride (JAN), is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia.[1][2] It is or has been marketed under brand names including Dipiperon, Dipiperal, Piperonil, Piperonyl, and Propitan.[2] Pipamperone was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963.[3]




Contents






  • 1 Pharmacology


  • 2 Antidepressant effects


  • 3 See also


  • 4 References





Pharmacology[edit]




Pipamperon Neuraxpharm, 40mg



Pipamperone acts as an antagonist of the 5-HT2A,[4]5-HT2B,[5]5-HT2C[6]D2,[4]D3,[7]D4,[4][8]α1-adrenergic,[7] and α2-adrenergic receptors.[7] It shows much higher affinity for the 5-HT2A and D4 receptors over the D2 receptor (15-fold in the case of the D4 receptor, and even higher in the case of the 5-HT2A receptor),[4][7][9] being regarded as "highly selective" for the former two sites at low doses.[9][10] Pipamperone has low and likely insignificant affinity for the H1 and mACh receptors, as well as for other serotonin and dopamine receptors.[7]


Pipamperone is considered to have been a forerunner to the atypical antipsychotics, if not an atypical antipsychotic itself, due to its prominent serotonin antagonism.[11][12][13]



Antidepressant effects[edit]


Low-dose pipamperone (5 mg twice daily) has been found to accelerate and enhance the antidepressant effect of citalopram (40 mg once daily), in a combination (citalopram/pipamperone) referred to as PipCit (code name PNB-01).[9][14]



See also[edit]



  • Clozapine

  • Melperone

  • Pimozide

  • Risperidone



References[edit]





  1. ^ Dr. Ian Morton; I.K. Morton; Judith M. Hall (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 222–. ISBN 978-0-7514-0499-9..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ ab J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 985–. ISBN 978-1-4757-2085-3.


  3. ^ David Healy (1 July 2009). The Creation of Psychopharmacology. Harvard University Press. pp. 251–. ISBN 978-0-674-03845-5.


  4. ^ abcd Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996). "Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding". Psychopharmacology. 124 (1–2): 57–73. doi:10.1007/bf02245606. PMID 8935801.


  5. ^ Wainscott DB, Lucaites VL, Kursar JD, Baez M, Nelson DL (1996). "Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences". J. Pharmacol. Exp. Ther. 276 (2): 720–7. PMID 8632342.


  6. ^ Prinssen EP, Koek W, Kleven MS (2000). "The effects of antipsychotics with 5-HT(2C) receptor affinity in behavioral assays selective for 5-HT(2C) receptor antagonist properties of compounds". Eur. J. Pharmacol. 388 (1): 57–67. doi:10.1016/s0014-2999(99)00859-6. PMID 10657547.


  7. ^ abcde Bart A. Ellenbroek; Alexander R. Cools (6 December 2012). Atypical Antipsychotics. Birkhäuser. pp. 62–. ISBN 978-3-0348-8448-8.


  8. ^ Van Craenenbroeck K, Gellynck E, Lintermans B, Leysen JE, Van Tol HH, Haegeman G, Vanhoenacker P (2006). "Influence of the antipsychotic drug pipamperone on the expression of the dopamine D4 receptor". Life Sci. 80 (1): 74–81. doi:10.1016/j.lfs.2006.08.024. PMID 16978659.


  9. ^ abc Wade AG, Crawford GM, Nemeroff CB, Schatzberg AF, Schlaepfer T, McConnachie A, Haazen L, Buntinx E (2011). "Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response". Psychol Med. 41 (10): 2089–97. doi:10.1017/S0033291711000158. PMID 21349239.


  10. ^ Michael S. Lidow (22 June 2000). Neurotransmitter Receptors in Actions of Antipsychotic Medications. CRC Press. pp. 88–. ISBN 978-1-4200-4177-4.


  11. ^ Awouters FH, Lewi PJ (2007). "Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen". Arzneimittelforschung. 57 (10): 625–32. doi:10.1055/s-0031-1296660. PMID 18074755.


  12. ^ Vanden Bussche G, Gelders YG, Heylen SL (1990). "[Development of new antipsychotic drugs]". Acta Psiquiatr Psicol Am Lat (in Spanish). 36 (1–2): 13–25. PMID 2127339.


  13. ^ Niemegeers CJ, Awouters F, Janssen PA (1990). "[Serotonin antagonism involved in the antipsychotic effect. Confirmation with ritanserine and risperidone]". Encephale (in French). 16 (2): 147–51. PMID 1693560.


  14. ^ Kirk R (2010). "Clinical trials in CNS--SMi's eighth annual conference". IDrugs. 13 (2): 66–9. PMID 20127552.













Retrieved from "https://en.wikipedia.org/w/index.php?title=Pipamperone&oldid=800155780"





Navigation menu


























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.968","walltime":"1.164","ppvisitednodes":{"value":5627,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":464219,"limit":2097152},"templateargumentsize":{"value":118311,"limit":2097152},"expansiondepth":{"value":16,"limit":40},"expensivefunctioncount":{"value":2,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":43880,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 750.436 1 -total"," 52.14% 391.246 1 Template:Drugbox"," 34.81% 261.247 1 Template:Infobox"," 25.01% 187.713 1 Template:Reflist"," 17.03% 127.815 22 Template:Navbox"," 11.32% 84.963 5 Template:Cite_book"," 10.64% 79.878 16 Template:Unbulleted_list"," 10.35% 77.670 1 Template:Navboxes"," 9.58% 71.917 9 Template:Cite_journal"," 7.07% 53.082 1 Template:Distinguish"]},"scribunto":{"limitreport-timeusage":{"value":"0.295","limit":"10.000"},"limitreport-memusage":{"value":6003709,"limit":52428800}},"cachereport":{"origin":"mw1318","timestamp":"20181231102643","ttl":1900800,"transientcontent":false}}});});{"@context":"https://schema.org","@type":"Article","name":"Pipamperone","url":"https://en.wikipedia.org/wiki/Pipamperone","sameAs":"http://www.wikidata.org/entity/Q415118","mainEntity":"http://www.wikidata.org/entity/Q415118","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png"}},"datePublished":"2006-11-13T20:37:18Z","dateModified":"2017-09-11T20:24:38Z","image":"https://upload.wikimedia.org/wikipedia/commons/5/56/Pipamperone.svg","headline":"chemical compound"}(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgBackendResponseTime":102,"wgHostname":"mw1238"});});
-

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as
Read more

Bicuculline

Image
Bicuculline From Wikipedia, the free encyclopedia Jump to navigation Jump to search Bicuculline Clinical data ATC code none Identifiers IUPAC name (6 R )-​6-​[(5 S )-​6-​methyl-​5,​6,​7,​8-​tetrahydro​[1,3]dioxolo​[4,5- g ]​isoquinolin-​5-​yl]​furo[3,4- e ]​[1,3]​benzodioxol-​8(6 H )-​one CAS Number 485-49-4   Y PubChem CID 10237 IUPHAR/BPS 2312 ChemSpider 9820   Y UNII Y37615DVKC ChEBI CHEBI:3092   N ChEMBL ChEMBL417990   N ECHA InfoCard 100.006.927 Chemical and physical data Formula C 20 H 17 N O 6 Molar mass 367.352 g/mol 3D model (JSmol) Interactive image Melting point 215 °C (419 °F) SMILES O=C1O[C@H](c3c1c2OCOc2cc3)[C@@H]5c4cc6OCOc6cc4CCN5C InChI InChI=1S/C20H17NO6/c1-21-5-4-10-6-14-15(25-8-24-14)7-12(10)17(21)18-11-2-3-13-19(26-9-23-13)16(11)20(22)27-18/h2-3,6-7,17-18H,4-5,8-9H2,1H3/t17-,18+/m0/s1   Y Key:IYGYMKDQCDOMRE-ZWKOTPCHSA-N
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校
Read more